open access

Vol 91, No 7 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-07-31
Get Citation

Retrospective analysis of the diagnostic effectiveness of the sentinel lymph node biopsy (SLNB) in vulvar cancer

Szymon Piatek, Wojciech Michalski, Malgorzata Benke, Anna Danska-Bidzinska, Mariusz Bidzinski
DOI: 10.5603/GP.2020.0079
·
Pubmed: 32779158
·
Ginekol Pol 2020;91(7):379-382.

open access

Vol 91, No 7 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-07-31

Abstract

Objectives: Inguinal lymphadenectomy used in the treatment of vulvar cancer often results in complications, such as
lymphoedema or abnormal wound healing. Aim of this study was assessment of the diagnostic effectiveness of the sentinel
lymph node biopsy (SLNB) procedure in patients treated due to vulvar cancer.
Material and methods: Eighty-four patients diagnosed with squamous cell vulvar carcinoma (FIGO I-IV) underwent
preoperative lymphoscintigraphy with technetium 99 to map sentinel lymph node. During surgery sentinel lymph nodes
were identified and resected, followed by complete bilateral groin lymphadenectomy.
Results: Sentinel lymph nodes were mapped with lymphoscintigraphy and biopsied in 84.3% and 90.1% of patients, respectively.
False negative predictive value (FNPV) was 9.1% and false negative rate (FNR) was recorded in 16.7% of cases. Patients
in advanced stages (FIGO III and IV) had significantly lower rate of lymphatic mapping compared to those in stage I and II
(OR = 0.148, p = 0.022). Detection of sentinel lymph node in lymphoscintigraphy for tumor grade 2 and 3 was nearly eight
times lower than for grade 1 cancers, however without statistical significance (OR = 0.126, p = 0.058).
Conclusions: The use of SLNB should be limited to vulvar cancer patients in early clinical stages.

Abstract

Objectives: Inguinal lymphadenectomy used in the treatment of vulvar cancer often results in complications, such as
lymphoedema or abnormal wound healing. Aim of this study was assessment of the diagnostic effectiveness of the sentinel
lymph node biopsy (SLNB) procedure in patients treated due to vulvar cancer.
Material and methods: Eighty-four patients diagnosed with squamous cell vulvar carcinoma (FIGO I-IV) underwent
preoperative lymphoscintigraphy with technetium 99 to map sentinel lymph node. During surgery sentinel lymph nodes
were identified and resected, followed by complete bilateral groin lymphadenectomy.
Results: Sentinel lymph nodes were mapped with lymphoscintigraphy and biopsied in 84.3% and 90.1% of patients, respectively.
False negative predictive value (FNPV) was 9.1% and false negative rate (FNR) was recorded in 16.7% of cases. Patients
in advanced stages (FIGO III and IV) had significantly lower rate of lymphatic mapping compared to those in stage I and II
(OR = 0.148, p = 0.022). Detection of sentinel lymph node in lymphoscintigraphy for tumor grade 2 and 3 was nearly eight
times lower than for grade 1 cancers, however without statistical significance (OR = 0.126, p = 0.058).
Conclusions: The use of SLNB should be limited to vulvar cancer patients in early clinical stages.

Get Citation

Keywords

sentinel lymph node procedure; vulvar cancer; retrospective analysis

About this article
Title

Retrospective analysis of the diagnostic effectiveness of the sentinel lymph node biopsy (SLNB) in vulvar cancer

Journal

Ginekologia Polska

Issue

Vol 91, No 7 (2020)

Pages

379-382

Published online

2020-07-31

DOI

10.5603/GP.2020.0079

Pubmed

32779158

Bibliographic record

Ginekol Pol 2020;91(7):379-382.

Keywords

sentinel lymph node procedure
vulvar cancer
retrospective analysis

Authors

Szymon Piatek
Wojciech Michalski
Malgorzata Benke
Anna Danska-Bidzinska
Mariusz Bidzinski

References (18)
  1. Hauspy J, Beiner M, Harley I, et al. Sentinel lymph node in vulvar cancer. Cancer. 2007; 110(5): 1015–1023.
  2. Wojciechowska U, Czaderny K, Ciuba A. et al. Cancer in Poland in 2016. , Warsaw 2018.
  3. Woelber L, Mahner S, Voelker K, et al. Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res. 2009; 29(2): 545–552.
  4. Frey JN, Hampl M, Mueller MD, et al. Should Groin Recurrence Still Be Considered as a Palliative Situation in Vulvar Cancer Patients?: A Brief Report. Int J Gynecol Cancer. 2016; 26(3): 575–579.
  5. Berek J, Hacker N. Practical Gynecologic Oncology, 3rd ed. Lippincott Williams & Wilkins, Baltimore 2000.
  6. Ansink AC, Sie-Go DM, van der Velden J, et al. Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a patent blue V injection: a multicenter study. Cancer. 1999; 86(4): 652–656, doi: 10.1002/(sici)1097-0142(19990815)86:4<652::aid-cncr14>3.0.co;2-r.
  7. de Hullu JA, Hollema H, Piers DA, et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol. 2000; 18(15): 2811–2816.
  8. Merisio C, Berretta R, Gualdi M, et al. Radioguided sentinel lymph node detection in vulvar cancer. Int J Gynecol Cancer. 2005; 15(3): 493–497.
  9. Sideri M, De Cicco C, Maggioni A, et al. Detection of sentinel nodes by lymphoscintigraphy and gamma probe guided surgery in vulvar neoplasia. Tumori. 2000; 86(4): 359–363.
  10. Rob L, Robova H, Pluta M, et al. Further data on sentinel lymph node mapping in vulvar cancer by blue dye and radiocolloid Tc99. Int J Gynecol Cancer. 2007; 17(1): 147–153.
  11. Vidal-Sicart S, Puig-Tintoré LM, Lejárcegui JA, et al. Validation and application of the sentinel lymph node concept in malignant vulvar tumours. Eur J Nucl Med Mol Imaging. 2007; 34(3): 384–391.
  12. McMasters KM, Wong SL, Chao C, et al. University of Louisville Breast Cancer Study Group. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg. 2001; 234(3): 292–9; discussion 299.
  13. Hassanzade M, Attaran M, Treglia G, et al. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013; 130(1): 237–245.
  14. Oonk MHM, Planchamp F, Baldwin P, et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer. 2017; 27(4): 832–837.
  15. NCCN Clinical Practice Guidelines in Oncology. Vulvar cancer version 2.2019. https://www2.tri-kobe.org/nccn/guideline/gynecological/english/vulvar.pdf (20.01.2020).
  16. Van der Zee AGJ, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008; 26(6): 884–889.
  17. Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012; 30(31): 3786–3791.
  18. Giammarile F, Bozkurt MF, Cibula D, et al. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur J Nucl Med Mol Imaging. 2014; 41(7): 1463–1477.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl